The Novel Study of IMOD TM against HIV-1, P24 production - ResearchGate
Combination of IMOD™ and Arbidol to increase their immunomodulatory effects as a novel medicine to prevent and cure influenza and some other infectious diseases
IMOD™ (Immuno-Modulator Drug), which is a patented herbal drug that improves the immune system, is formulated from three herbal extracts of
Tanacetum vulgare,
Urtica dioica, and
Rosa canina, which is then enriched with selenium
[1]. This drug is used for the treatment of human immunodeficiency virus (HIV) infection by increasing CD4 lymphocytes
[2]. These cells are measured in the blood as CD4 and CD8 counts
[3]. The CD4 count is a reflection of immune system efficiency: the lower the CD4 count, the weaker the immune system will be. If the CD4 count is <200 in a microliter of blood, the person is considered to be infected and is involved with AIDS
[4]. In fact, patients with a CD4 count of <400 showed a significant increase in their CD4 counts following treatment with IMOD™ for 3 months in comparison to those in a control group who were not treated with IMOD™
[5]. Therefore, this viral infection disease can be treated with an increasing number of CD4 lymphocytes in the blood
[6]. In addition, the presence of selenium as an immune booster and the presence of flavonoids such as chlorogenic acid, caffeic acid, kaempferol, esculetin, apigenin, luteolin, rutin, ferulic acid, etc., which have antioxidant effects, help to remove free radicals and improve the immune system as well.
On the other hand, Arbidol, which is a synthetic broad-spectrum antiviral agent
[7], has immunomodulating effects and is an interferon-inducing agent. Therefore, the agent can improve CD4 counts
[8] as well. Arbidol inhibits the fusion of influenza A and B (N1H1, N2H2, N2H3, and avian influenza viruses of N1H5 and H9N1) and has the same effect on severe acute respiratory syndrome (SARS) viruses that interact with cell membranes. Additionally, the agent inhibits acute and chronic hepatitis C virus infection
[8] and
[9]. Furthermore, Arbidol has antioxidant properties and is in the category of the least toxic drugs (LD50 > 4 g/kg) which does not have adverse effects on the human body when taken orally at the recommended dosages
[9].
Conclusion
In this context, we proposed a novel idea to prevent and treat viral infections such as influenza diseases. As discussed above, IMOD™ has been used successfully within the last few years, resulting in increased CD4 lymphocyte counts and consequent improvement of the immune system. Similarly, Arbidol also by itself has proven within the last two decades to be a safe and effective drug for the prevention and treatment of flu and influenza. Therefore, with the advantage of both medicines, a stronger choice to prevent and cure not only flu but also some other infectious diseases such as acute hepatitis B and C can also be targeted. In a large sample of gatherings such as the
Hajj pilgrimage where millions of Muslims are in close contact while performing their religious obligations, the viruses can be transferred with ease by sneezing and coughing. Testing the idea in several groups of attendees could prove the safety and the efficacy of the above combination in a clinical trial. Such results will be published and the whole society can benefit, especially during the flu seasons of the year. This strategy will also help to stop the spreading of such viruses to other countries. Moreover, the mass production of such a beneficial medicine in different forms such as capsules, tablets, and probably ampoules are proposed if biological tests prove promising.
=========================================
HARARE - Visiting Iranian delegation from the Centre of Innovation and Technology Co-operation (CITC) has agreed to partner the Harare Institute of Technology (HIT) in setting up facilities to produce life-prolonging drugs. This deal could help the country save millions of dollars on drug imports and offer hope to HIV-positive people in the face of critical shortages of anti-retrovirals. Head of delegation and head of the Centre for Innovation and Technology Co-operation in Iran, Prof Hamid Reza Amirinia said his country was committed to working with HIT in the manufacture of the Immuno-Modulator Drug (IMOD) drug for people living with HIV and AIDS.
IMOD is a name given to a herbal drug that, according to Iranian scientists, protects those already infected by HIV by strengthening the immune system.“We were in conversation with the Minister of Health and Child Care, Dr (David) Parirenyatwa yesterday discussing the need to introduce IMOD drug to assist people living with HIV and AIDS in Zimbabwe and be able to work with HIT in the manufacturing of the drug so that it would be readily available in Africa,” he said. “We have notable achievements in the areas of medical biotechnologies in Iran and the use of the IMOD drug is among our greatest achievements.” The life prolonging drug, he said, helps stimulate the immune system and prevents patients with HIV from entering the AIDS stage while also helping patients with AIDS recover and experience a normal life.
“The herbal-made medication serves to rein in the AIDS virus and redouble the body’s immunity. It is not a medication to completely kill the virus and can be used besides other anti-retroviral drugs.” Said Prof Amirinia. He said the IMOD drug was safe and had no proven side effects and could also be used on all diseases related to the immune system. HIT acting vice chancellor Engineer Quinton Kanhukamwe expressed gratitude to the Iranian delegation for their commitment to this initiative saying it would help develop the country. “We welcome this initiative since this visit is a follow up to the first visit which saw us signing an agreement to collaborate technologies from Tehran University in Iran and HIT,” he said.
“We recently acquired a licence from the Ministry of Health to start the IMOD pilot project which we hope to commence soon so that if we are successful, the institute will then roll out the project on a national scale.”
Eng Kanhukamwe said the two countries would soon start an exchange programme for students from both countries to share experiences and collaborate in various research programmes.
“Such initiatives help us to focus on solutions to the real challenges that affect Zimbabweans,’ he said.
IMOD was made public in February 2007 in Iran and the drug, made from medicinal plants in 15 research centres around Iran, controls the spread of the virus in the blood stream and boosts immunity with a 90-day treatment course and a two-year follow up.
The drug took five years to develop and tests on 200 patients proved successful.
New ARVs deal for Zimbabwe | National AIDS Council of Zimbabwe
================
these are all extremely credible sources like ELSEVIER and Sciencedircet (except the last one which is a news ) .
so my point is . iranians are mostly blind dumdums that easily fall for any propaganda they are fed
